On August 8, 2022, Atara Biotherapeutics, Inc. announced a reduction in its workforce plan that will impact approximately 20% of its current employees. The Company expects to substantially complete the workforce reduction by October 7, 2022. In connection with the reduction in workforce, the employment of Kristin Yarema, the Company's Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5636 USD | -2.51% | -7.83% | +9.91% |
May. 20 | Sector Update: Health Care Stocks Ease Monday Afternoon | MT |
May. 20 | Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.91% | 68.4M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- ATRA Stock
- News Atara Biotherapeutics, Inc.
- Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022